# Phase 3 Cardiovascular Diseases trials recruiting: 22 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials in phase 3 for Cardiovascular Diseases that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Cardiovascular Diseases trials: 22 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/cardiovascular-diseases

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07918846 | A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Overweight, Obesity, Cardiovascular Disease | 8,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918846) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 13, 2026 | NCT07872046 | A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults \>=50 Years of Age With Established... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Cardiovascular Disease | 16,390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872046) |
| September 28, 2026 | NCT07843472 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established... | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Cardiovascular Disease | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843472) |
| September 11, 2026 | NCT07816185 | A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) | Pulmovant, Inc. | Phase 3 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816185) |
| May 29, 2026 | NCT07613294 | A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High... | Eli Lilly and Company | Phase 3 | Recruiting | Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a) | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613294) |
| May 29, 2026 | NCT07613099 | Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | Recruiting | Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury... | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613099) |
| December 19, 2025 | NCT07293260 | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial | Amgen | Phase 3 | Recruiting | Cardiovascular Disease | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07293260) |
| November 24, 2025 | NCT07245680 | COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities | Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD) | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07245680) |
| September 18, 2025 | NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for... | Alnylam Pharmaceuticals | Phase 3 | Recruiting | High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk | 11,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181109) |
| August 22, 2025 | NCT07136012 | OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events | Amgen | Phase 3 | Recruiting | Cardiovascular Disease | 11,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136012) |
| July 14, 2025 | NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood... | Boehringer Ingelheim | Phase 3 | Recruiting | Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases | 11,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07064473) |
| June 2, 2025 | NCT07000357 | A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event | AstraZeneca | Phase 3 | Recruiting | Cardiovascular Disease | 15,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07000357) |
| September 19, 2024 | NCT06597019 | Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia | Novartis Pharmaceuticals | Phase 3 | Recruiting | Familial Hypercholesterolemia - Heterozygous | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06597019) |
| September 19, 2024 | NCT06597006 | Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia | Novartis Pharmaceuticals | Phase 3 | Recruiting | Familial Hypercholesterolemia - Homozygous | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06597006) |
| February 26, 2024 | NCT06279000 | Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery | Cantonal Hospital of St. Gallen | Phase 3 | Recruiting | Cardiovascular Diseases, Cardiovascular Complication, Perioperative Complication, Myocardial Injury, Myocardial Injury... | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06279000) |
| January 22, 2024 | NCT06217302 | Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Sponsor not shown (see the record) | Phase 3 | Recruiting | Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06217302) |
| October 13, 2023 | NCT06082063 | Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes | Steno Diabetes Center Copenhagen | Phase 3 | Recruiting | Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney Failure | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06082063) |
| July 13, 2023 | NCT05943821 | The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk | Poznan University of Medical Sciences | Phase 3 | Recruiting | Cardiovascular Diseases, Uric Acid | 1,116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05943821) |
| July 5, 2023 | NCT05931276 | CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | VA Office of Research and Development | Phase 3 | Recruiting | End-Stage Kidney Disease, End-Stage Renal Disease | 2,540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05931276) |
| December 1, 2022 | NCT05633810 | COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes | Montreal Heart Institute | Phase 3 | Recruiting | Diabete Type 2, Cardiovascular Diseases | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05633810) |
| February 25, 2022 | NCT05257629 | Aggressive Smoking Cessation Trial (ASAP) | Sir Mortimer B. Davis - Jewish General Hospital | Phase 3 | Recruiting | Acute Coronary Syndrome, Cardiovascular Diseases | 798 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05257629) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| VA Office of Research and Development | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Steno Diabetes Center Copenhagen | 1 |
| Pulmovant, Inc. | 1 |
| Montreal Heart Institute | 1 |
| Sir Mortimer B. Davis - Jewish General Hospital | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Poznan University of Medical Sciences | 1 |
| Cantonal Hospital of St. Gallen | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| [Alnylam Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/alnylam-pharmaceuticals) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| Canada | 9 |
| China | 8 |
| France | 8 |
| Australia | 7 |
| Germany | 7 |
| Italy | 7 |
| Spain | 7 |
| United Kingdom | 7 |
| Czechia | 6 |
| Denmark | 6 |
| Greece | 6 |
| Hungary | 6 |
| Netherlands | 6 |
| Poland | 6 |
| Taiwan | 6 |
| Turkey (Türkiye) | 6 |
| Argentina | 5 |
| Brazil | 5 |
| Japan | 5 |
| South Africa | 5 |
| Austria | 4 |
| India | 4 |
| Malaysia | 4 |
| Mexico | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Salvadoran restaurants in the United States](https://specstream.ai/data/businesses/salvadoran-restaurants/united-states)
- [Bottled water companies in the United States](https://specstream.ai/data/businesses/bottled-water-companies/united-states)
- [Hydraulic equipment suppliers in the United States](https://specstream.ai/data/businesses/hydraulic-equipment-suppliers/united-states)
- [Septic services in the United States](https://specstream.ai/data/businesses/septic-services/united-states)
- [Business banking companies in the United States](https://specstream.ai/data/businesses/business-banking-companies/united-states)
- [Industrial equipment manufacturers in the United States](https://specstream.ai/data/businesses/industrial-equipment-manufacturers/united-states)
